KYG0411D1079 - Common Stock
加利福尼亚州福斯特城, Dec. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (简称 “Apollomics” 或 “公司”)...
福特斯城,加州, Dec. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (「Apollomics」或「該公司」) 是一家後期臨床生物製藥公司,開發多種腫瘤候選藥物以解決難治性和對治療有抗藥性的癌症。該公司今日公布了其藥物...
FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...
FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company...
The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024
The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024...
Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplification
FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...
Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung...
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusions
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses)...
FOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...
Pre-market stock movers are worth diving into this morning and we have all of the hottest news worth checking out on Thursday!
FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need...
Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations
Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the...